急性心力衰竭治疗的新药重组人松弛素

Serelaxin:a Potential New Drug for the Treatment of Acute Heart failure

目的:最近重组人松弛素的临床试验为急性心力衰竭(AHF)的治疗提供了新的希望,笔者主要对重组人松弛素的作用机制、药理学特性、临床特征及治疗AHF的作用做一综述。方法:使用Pubmed/Medline database对文献进行查找,收集到21篇相关文献。结果 :研究表明重组人松弛素显著改善AHF患者的症状,缩短住院时间,降低病死率。目前的资料表明这些临床益处与重组人松弛素的多效性有关,包括改善全身、心脏和肾脏血流动力学,通过抗炎、抗细胞死亡、抗纤维化、抗心肌肥厚及促进血管新生保护细胞和器官免受损伤。结论 :重组人松弛素是一种有前景的治疗AHF药物。正在进行中的研究旨在验证先前的试验结果、安全性和血流动力学效应,探讨这些效应的分子机制。

Objective：Recent clinical trials of serelaxin have provided a new hope in acute heart failure （AHF）.Serelaxin mechanisms,pharmacology,clinical features and its potential role in AHF are reviewed here.Methods：Twenty one articles were identified through a literature search of the Pubmed and Medline database.Results：Clinical trials have demonstrated significant serelaxin-related improvement in heart failure symptoms,length of hospital stay as well as mortality reduction in AHF patients.Available data suggested that the clinical benefits may be attributable to a potential combination of multiple actions of serelaxin,including improving systemic,cardiac,and renal hemodynamics,and protecting cells and organs from damage via anti-inflammatory,anti-cell death,anti-fibrotic,antihypertrophic,and pro-angiogenic effects.Conclusion：Serelaxin is a promising therapy,and further studies aimed at reproducibility of prior results,safety and hemodynamic effects of serelaxin,as well as investigation of the molecular reasons for such effects are currently under way.